Aurobindo Pharma. has filed a patent for a stable immediate release tablet containing Ubrogepant and specific polymers, prepared using a hot melt extrusion process. This innovation aims to improve drug delivery efficiency. GlobalData’s report on Aurobindo Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aurobindo Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Aurobindo Pharma's grant share as of January 2024 was 72%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20230390254A1) describes a stable immediate release tablet containing Ubrogepant and a water insoluble polymer prepared through a hot melt extrusion process. The tablet also includes a plasticizer, dispersing agent, disintegration system, and other pharmaceutically acceptable excipients. The plasticizer can be triethyl citrate or polyethylene glycol, while the dispersing agent is tocopherol-polyethylene-glycolsuccinate, and the disintegration system consists of sodium chloride and conventional disintegrants like croscarmellose sodium. The tablet's excipients may include diluents like microcrystalline cellulose, glidants such as colloidal silicone dioxide, and lubricants like magnesium stearate.
Furthermore, the patent application details different formulations of the stable immediate release tablet, varying in the composition of Ubrogepant, water insoluble polymer, plasticizers, dispersing agents, and other excipients. The tablets are prepared using a hot melt extrusion process and are devoid of solid dispersions or extrudates containing Ubrogepant. The formulations may include polyvinylpyrrolidone vinylacetate copolymers as the water-soluble polymer, with additional components like crospovidone and low-substituted hydroxypropyl cellulose in the disintegration system. The tablets aim to provide immediate release of Ubrogepant for effective treatment, with specific weight percentages of each component carefully outlined in the claims for optimal performance.
To know more about GlobalData’s detailed insights on Aurobindo Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
